Cycle on Oct 5, 2026

I'll start this research cycle by checking open threads and pulling market data for the core companies named in the brief.

I have the market snapshot. Two things jump out immediately: **NVO is down 21.4% in a month (RSI 21)** and **GPCR is down 41.6% in a month (RSI 16)** — sharp moves that need explaining. VKTX also had a big $575M raise plus a 36% data-driven spike. Let me search for what's driving these moves and any other GLP-1 news.

The Fierce Pharma Oral GLP-1 Tracker content came through in full — Foundayo is now accelerating (64K scripts) while the Wegovy pill stalls. Let me dig into the GPCR collapse, the Novo slide drivers, and adjacent-sector effects.

No single discrete catalyst surfaced for GPCR's slide — it looks like a grind (oral GLP-1 premium thesis compressing as Foundayo scales, plus an EPS miss). Now let me fetch the actual pages I'll cite: the Fierce oral tracker, the Viking maintenance-data coverage, the EASD/Lilly indirect-comparison piece, the amylin next-gen piece, the food-industry ripple article, and the Wegovy pill switch study.

The Fierce tracker fetch timed out, but the full article text came through in the search results. Let me retry it once since it's the anchor source for the oral GLP-1 battle update.

I have all the evidence I need. Now I'll write the findings — one note per theme, updating existing slugs where the subject continues. First batch of three:

First note saved. The second call was malformed — let me write the remaining notes properly, starting with the EASD competitive-landscape update and the Viking note.

Two more saved. Now the adjacent-sector finding and the Novo and pricing updates:

Now the pricing/reimbursement update:

All findings are persisted. Now recording the open question on GPCR and the forward-looking watches this cycle surfaced:

Both watches registered. The thread call rejected the kind — retrying with `question`:

Thread recorded. The cycle is complete — wrapping up:

Cycle complete. Here's what this research cycle found: ## Key developments (week of Sept 29 – Oct 5, 2026) **1. The oral GLP-1 battle flipped** — Lilly's Foundayo surged 21% to 64,268 weekly scripts (after +13% the prior week) while Novo's Wegovy pill stalled at ~182K for five straight weeks. Lilly now owns 26% of the oral market (up from <23%), helped by the Martha Stewart DTC ad, the Medicare Bridge, and a Sept 1 starter-dose price cut to $149/$199. Zepbound still leads all of obesity at 805.7K weekly scripts; the market split holds ~60/40 Lilly/Novo. *Updated: `eli-lilly-foundayo-orforglipron-fda-approval`* **2. EASD 2026 made amylin the next frontier** — Lilly's EloraTZP (eloralintide+tirzepatide) hit 23% weight loss vs 14.8% for tirzepatide alone; Novo's CagriSema showed 22.4% plus "food noise" brain data; Zealand's petrelintide posted placebo-like tolerability. Lilly also escalated indirect head-to-head claims (Foundayo > oral semaglutide; Zepbound > high-dose Wegovy). Challenger wave: Pfizer's monthly shot, Amgen's MARITIME-SWITCH, AbbVie's amylin, and a surge of China-licensed molecules. *Updated: `glp1-competitive-landscape-ada-2026`* **3. Novo's slide deepened** — NVO is at $37.32, **down 21.4% in a month** (RSI 21, 9.4 P/E, ~70% off peak), on the pill stall, 108 more NJ job cuts, and a denecimig facility-remediation delay. CagriSema's Q4 FDA decision is the nearest catalyst. *Updated: `novo-nordisk-capital-markets-day-2030-strategy`* **4. Viking's maintenance win + dilution** — VK2735 kept 97% (every-other-week) / 90% (monthly) of weight loss vs 61% placebo, sparking a 36% spike — followed days later by a $575M dilutive raise that roughly quintupled runway. *New: `viking-vk2735-maintenance-data-financing`* **5. Reimbursement reset** — Medicare GLP-1 Bridge reached ~700K seniors at $50 copays with Lilly taking 7 of 10 patients; cash Wegovy is down 75% since 2021. *Updated: `glp1-pricing-trumprx-list-price-cuts`* **6. Food ripple effects quantified** — Cornell: grocery spending falls 5–8% within six months of a household adopting a GLP-1, with snacks (PEP, HSY, MDLZ) most exposed. *New: `glp1-food-beverage-ripple-effects`* **Open question + new watches:** GPCR's 41% one-month collapse had no single confirmed catalyst (thread opened to investigate before its Q4 SWITCH/Body-Composition readouts). Registered ongoing watches on Medicare Bridge enrollment dynamics and a Foundayo oral-share >30% tripwire. Q3 earnings (LLY late Oct, NVO early Nov) remain the next major catalyst on the existing watch.